Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07318363 · ClinicalTrials.gov registry record · Phase 3
IGNITE-TX Phase III: (Identifying Individuals for Genetic Testing & Treatment) Intervention
A Phase 3 study, sponsored by M.D. Anderson Cancer Center.
- Not yet
- Registry status
- Phase 3
- Development phase
- 2,100
- Enrollment target
NCT07318363: Clinical Trial Phase 3 study, sponsored by M.D. Anderson Cancer Center.
NCT07318363 is a Phase 3 study that has not yet begun recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 2,100 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (172% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07318363, a Phase 3 study, has not yet begun recruiting, sponsored by M.D. Anderson Cancer Center.
- NOT YET RECRUITING
- Registry status
- Phase 3
- Development phase
- 2,100 participants
- Enrollment target
Study Summary
This trial aims to implement and compare an evidence- and theory-based intervention strategy (IGNITE-TX Intervention) to support probands and their ARRs in family communication, informed decision-making, and navigation to CGT with standard of care, free genetic testing/counseling, and intervention with free genetic testing/counseling.
Primary Outcome
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0
Interventions
- OTHER IGNITE-TX program
- OTHER Genetic Counseling and Testing
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,100 participants |
| Start Date | 2026-06-01 |
| Est. Completion | 2032-04-01 |
| Phase | Phase 3 |
What is known before NCT07318363 opens enrollment
NCT07318363 is an interventional study that assigns participants to a tested intervention. Its 2,100 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (172% higher).
The record links to 0 conditions, and to 2 interventions - of which IGNITE-TX program is the first listed.
NCT07318363 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07318363 about?
NCT07318363 is a clinical study titled "IGNITE-TX Phase III: (Identifying Individuals for Genetic Testing & Treatment) Intervention". This trial aims to implement and compare an evidence- and theory-based intervention strategy (IGNITE-TX Intervention) to support probands and their ARRs in family communication, informed decision-making, and navigation to CGT with standard of care, free genetic testing/counseling, and intervention w...
What is the current status of trial NCT07318363?
This trial is currently not yet recruiting. It is a Phase 3 study. The enrollment target is 2,100 participants. The study started on 2026-06-01. Estimated completion is 2032-04-01.
What interventions are being tested in trial NCT07318363?
The interventions under investigation include: IGNITE-TX program (OTHER), Genetic Counseling and Testing (OTHER).
Who is sponsoring clinical trial NCT07318363?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07318363's enrollment target sits among peer trials
2,100 98th of 2000 higher than 1,902 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04649242 · 2,100 participants · Phase 3
Randomized Study in Children and Adolescents With Migraine: Acute Treatment
- NCT05206331 · 2,100 participants · Phase 4
CEM to Reduce Biopsy Rates for Less Than Highly Suspicious Breast Abnormalities: a Prospective Study
- NCT05270499 · 2,100 participants
Aveir VR Real-World Evidence Post-Approval Study
- NCT06324981 · 2,100 participants · NA
Using AI Text Messaging to Improve AHA's Life's Essential 8 Health Behaviors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI